Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study — Steven Deitelzweig (2022) | RDL Network
Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
Article 2022 en
Authors
SD
Steven Deitelzweig
AK
Allison Keshishian
AK
Amiee Kang
Abstract
1 min read
Over 12 months after initiation, apixaban and dabigatran conferred progressive increases in event free time for stroke/SE and MB vs warfarin, whereas rivaroxaban conferred an increase in stroke/SE-free time but a loss in MB-free time vs warfarin.
Steve Deitelzweig, Allison Keshishian, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Xiaoyan Li, Neeraja Balachander, Lisa Rosenblatt, Jack Mardekian, Xianying Pan, Manuela Di Fusco, Alessandra Bassalobre García, Hüseyin Yüce, Professor Gregory Lip
Professor Gregory Lip, Allison Keshishian, A Kang, X Luo, Nipun Atreja, Y Zhang, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Steven Deitelzweig
Professor Gregory Lip, Allison Keshishian, A Kang, X Luo, Nipun Atreja, Y Zhang, Patricia Schuler, Jenny Jiang, K Lovett, Hüseyin Yüce, Steven Deitelzweig
Discussion(0)
No comments yet. Be the first to comment.